Navigation Links
CVS Caremark Reiterates Support for FDA Implementation of Approval Pathway for Biogeneric Drugs

WOONSOCKET, R.I., Nov. 2, 2010 /PRNewswire/ -- CVS Caremark reiterated the company's support that the U.S. Food and Drug Administration (FDA) implement regulations necessary to approve biogeneric drugs under the Affordable Care Act. The company's Senior Vice President of Specialty Pharmacy Operations, Scott Reid, testified before the FDA today during a public hearing to address the development of an approval pathway for biosimilar and interchangeable biological products held at the agency's headquarters in Silver Spring, Maryland.



"Every day CVS Caremark supports patients who depend on specialty and other biotech drugs to provide critical treatment for their serious, chronic conditions, and we have long advocated for the creation of an FDA pathway for approval of biogeneric options," said Reid. "The availability of biogenerics will not only help health plans, employers and federal programs manage their drug spend, but, more importantly, it will help make these extremely expensive medicines more affordable for patients."

Reid's comments to the agency also touched on ensuring that pharmacovigilance programs for biosimilar and interchangeable products are consistent with programs for the innovator products and that additive burdens, that could inhibit patient access, are not imposed on pharmacies at the front lines of managing these programs.  He also urged the FDA to work with the Centers of Medicare and Medicaid Services to establish a regulatory process that not only allows for interchangeability of biologics but also aligns reimbursement incentives for payers, patients and providers to choose a biogeneric.

About CVS CaremarkCVS Caremark is the largest pharmacy health care provider in the United States. Through our integrated offerings across the entire spectrum of pharmacy care, we are uniquely positioned to provide greater access, to engage plan members in behaviors that improve their health and to lower overall health care costs for health plans, plan sponsors and their members. CVS Caremark is a market leader in mail order pharmacy, retail pharmacy, specialty pharmacy, and retail clinics, and is a leading provider of Medicare Part D Prescription Drug Plans. As one of the country's largest pharmacy benefits managers (PBMs), we provide access to a network of more than 64,000 pharmacies, including approximately 7,100 CVS/pharmacy® stores that provide unparalleled service and capabilities. Our clinical expertise includes one of the industry's most comprehensive disease management programs. General information about CVS Caremark is available through the Company's Web site at Contact:Jon SandbergCVS

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CVS Caremark to Present at Credit Suisse Annual Healthcare Conference
2. CVS Caremark Corporation to Hold Third Quarter 2010 Conference Call
3. CVS Caremark Research Highlights How Innovative Plan Designs Help Clients Reduce Drug Spend and Improve Generic Dispensing Rates
4. CVS Caremark Ready to Support Patients and Payors Through Coming Era of Health Care Expansion
5. CVS Caremark Appoints Jonathan C. Roberts as PBM Chief Operating Officer
6. CVS Caremark Recognizes Its 26,000 Pharmacists During Octobers American Pharmacists Month
7. NCPA Commends Senate Aging Committee for Launching CVS Caremark Investigation to Examine Alleged Harm to Seniors, Medicare
8. CVS Caremark Announces 2010 Analyst Day
9. CVS Caremark Corporation Announces Quarterly Dividend
10. CVS Caremark Maintenance Choice Program Improves Medication Adherence for US Airways Employees and Dependents
11. CVS Caremark Presents Ongoing Behavioral Change Research Partnership Research to the Pittsburgh Business Group on Health
Post Your Comments:
(Date:11/26/2015)... Carolina , 26 november 2015 /PRNewswire/ ... (AAIPharma/CML) kondigt de geplande investering aan van ... van de laboratoria en het mondiale hoofdkantoor ... De uitbreiding zal resulteren in extra kantoorruimte ... voldaan aan de groeiende behoeften van de ...
(Date:11/26/2015)... , November 26, 2015 --> ... to use SyMRI to find optimal contrast weighting of MRI ... metastases, and has signed a research agreement with SyntheticMR in ... hospital. Using SyMRI, it is possible to generate multiple contrast ... after the patient has left, thus making it possible to ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Japanese therapeutic drug monitoring market, including ...
Breaking Medicine Technology:
(Date:11/27/2015)... , ... November 27, 2015 , ... ... November 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South ... 750,000. The digital component is distributed nationally, through a vast social media strategy ...
(Date:11/27/2015)... ... ... No.1 Herpes-only dating community in the world, revealed that over 50% of its members are ... people under the age of 50 – or 67% of the population - are infected ... HSV-1 infection . , "The data shocks us highly!" said Michelle Li, Co-Founder of ...
(Date:11/27/2015)... ... 27, 2015 , ... Intellitec Solutions announced today that they ... Recognized as Microsoft’s official group for end users of Dynamics SL ERP software, ... industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ongoing commitment to ...
(Date:11/27/2015)... MINNEAPOLIS, Minn. (PRWEB) , ... November 27, 2015 ... ... you start failing. Secura Consultants has prided itself for not only fulfilling the ... best income protection solutions at an affordable price and providing top-tier customer service. ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is ... Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College ... as only one of twelve colleges and universities in the state of California make ...
Breaking Medicine News(10 mins):